Nurix Discontinued Clinical Development of Zelebrudomide
The company has ended the program to focus resources on its oncology portfolio and its partnership with Roche.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when deciding which drugs to develop?
Nurix has officially ceased the clinical development of its BTK degrader zelebrudomide to prioritize its own oncology pipeline. The decision follows a review of clinical data, though patients currently receiving the treatment may continue if clinically appropriate.
Why it matters
By discontinuing this program, the company aims to streamline its focus toward wholly owned assets and its strategic collaboration with Roche on other degrader technologies. This shift emphasizes a broader shift in focus toward bexobrutideg, a BTK degrader currently moving into Phase 3 clinical trials.
Nurix recently completed an enrollment phase for a study of zelebrudomide that faced an FDA clinical hold. Development of the platform is being superseded by the company's advancement of bexobrutideg.
The players
Nurix
Nurix is a California-based biotechnology company focused on the discovery and development of novel small-molecule therapies.
Roche
Roche is a multinational healthcare company that develops pharmaceuticals and diagnostics.
The details
The firm, based in California, reached this decision after reviewing clinical trial data and determining that focusing on its partnership with Roche offered greater strategic potential. The company expects these newer degraders to provide significant clinical advantages over traditional BTK inhibitor products currently available on the market.
Timeline
November 2023: The FDA placed a clinical hold on the zelebrudomide study.
March 2024: The FDA lifted the clinical hold on the zelebrudomide study.
June 2026: Roche paid $700 million upfront for rights to bexobrutideg.
July 2026: Nurix reviewed the clinical data for zelebrudomide.
October 12, 2026: Nurix announced the discontinuation of zelebrudomide.
The Tech Race
The transition away from zelebrudomide reflects a competitive arms race in the development of targeted protein degraders. By doubling down on its partnership for bexobrutideg, Nurix seeks to secure a stronger position in the oncology market against existing BTK inhibitor standards.
Patients currently enrolled in the zelebrudomide clinical trial should consult with their healthcare providers regarding the continuity of their treatment plans. For the broader industry, this shift may impact the speed and availability of future targeted oncology therapies currently in development.
The takeaway
Companies frequently reallocate research funds to maximize the potential of their most promising therapeutic candidates. Investors and patients should monitor how the transition toward bexobrutideg influences the company's clinical timelines and future success in the oncology space.
Further reading
Learn more about the latest developments in the sector at Biotech.
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when deciding which drugs to develop?
